A review of data from published studies of all the somatostatin analogues suggested that tumor volume reduction is progressive with prolonged treatment, and that decreased IGF-1 levels are the best predictor of tumor volume reduction, followed by age and degree of GH decrease [63]. This evidence concerns the gene GH1 and neoplasm.